

Sub  
B1  
21. A pharmaceutical composition containing one or more anti-EPO antibodies as claimed in claim 17.

22. A method for purifying EPO, EPO derivatives or EPO peptides by using one or more anti-EPO antibodies as claimed in claim 17.

23. An anti-EPO antibody as claimed in claim 5, which is directed against epitopes which bind to the EPO receptor.--  
mb DS

**REMARKS**

Claims 5, 6, 7, 12, 14 and 15 have been amended. Claims 17-23 have been newly added. Claim 1 has been canceled.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER

By: Carol P. Einaudi  
Carol P. Einaudi  
Reg. No. 32,220

Date: July 21, 1997

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000